Risks factors for event-free survival and overall survival
| Outcomes . | Events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Event-free survival | |||
| Age at transplantation, y | |||
| ≤6 | 84/638 | 1.00 | <.001 |
| 7-15 | 87/439 | 1.46 (1.07-2.00) | .017 |
| 16-25 | 14/33 | 3.03 (1.68-5.47) | <.001 |
| Donor type | |||
| HLA-matched relative | 108/677 | 1.00 | <.001 |
| HLA-mismatched relative | 29/78 | 2.75 (1.81-4.16) | <.001 |
| HLA-matched unrelated | 26/252 | 1.25 (0.75-2.07) | .39 |
| HLA-mismatched unrelated | 22/103 | 1.60 (0.95-2.71) | .08 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 28/376 | 1.00 | <.001 |
| Bu/Cy/FLU | 27/259 | 1.32 (0.78-2.25) | .31 |
| Bu/Cy | 71/249 | 3.11 (1.80-5.40) | <.001 |
| Treosulfan/TT/FLU | 38/169 | 2.79 (1.61-4.83) | <.001 |
| Bu or melphalan ± TT ± FLU | 21/57 | 5.09 (2.81-9.21) | <.001 |
| Transplant period | |||
| 2012-2016 | 74/657 | 1.00 | .008 |
| 2006-2011 | 73/339 | 1.66 (1.17-2.35) | .01 |
| 2000-2005 | 38/114 | 1.96 (1.16-3.33) | .01 |
| Overall survival | |||
| Age at transplantation, y | |||
| ≤6 | 57/638 | 1.00 | <.001 |
| 7-15 | 73/439 | 1.84 (1.29-2.63) | <.001 |
| 16-25 | 12/33 | 4.35 (2.28-8.30) | <.001 |
| Donor type | |||
| HLA-matched relative | 83/677 | 1.00 | <.001 |
| HLA-mismatched relative | 25/78 | 3.30 (1.93-4.77) | <.001 |
| HLA-matched unrelated | 19/252 | 1.13 (0.64-2.02) | .67 |
| HLA-mismatched unrelated | 15/103 | 1.56 (0.85-2.88) | .16 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 25/376 | 1.00 | <.001 |
| Bu/Cy/FLU | 22/259 | 1.32 (0.74-2.34) | .34 |
| Bu/Cy | 55/249 | 3.61 (2.15-6.07) | <.001 |
| Treosulfan/TT/FLU | 30/169 | 2.22 (1.23-4.030 | .008 |
| Bu or melphalan ± TT ± FLU | 10/57 | 2.55 (1.18-5.50) | .02 |
| Outcomes . | Events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Event-free survival | |||
| Age at transplantation, y | |||
| ≤6 | 84/638 | 1.00 | <.001 |
| 7-15 | 87/439 | 1.46 (1.07-2.00) | .017 |
| 16-25 | 14/33 | 3.03 (1.68-5.47) | <.001 |
| Donor type | |||
| HLA-matched relative | 108/677 | 1.00 | <.001 |
| HLA-mismatched relative | 29/78 | 2.75 (1.81-4.16) | <.001 |
| HLA-matched unrelated | 26/252 | 1.25 (0.75-2.07) | .39 |
| HLA-mismatched unrelated | 22/103 | 1.60 (0.95-2.71) | .08 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 28/376 | 1.00 | <.001 |
| Bu/Cy/FLU | 27/259 | 1.32 (0.78-2.25) | .31 |
| Bu/Cy | 71/249 | 3.11 (1.80-5.40) | <.001 |
| Treosulfan/TT/FLU | 38/169 | 2.79 (1.61-4.83) | <.001 |
| Bu or melphalan ± TT ± FLU | 21/57 | 5.09 (2.81-9.21) | <.001 |
| Transplant period | |||
| 2012-2016 | 74/657 | 1.00 | .008 |
| 2006-2011 | 73/339 | 1.66 (1.17-2.35) | .01 |
| 2000-2005 | 38/114 | 1.96 (1.16-3.33) | .01 |
| Overall survival | |||
| Age at transplantation, y | |||
| ≤6 | 57/638 | 1.00 | <.001 |
| 7-15 | 73/439 | 1.84 (1.29-2.63) | <.001 |
| 16-25 | 12/33 | 4.35 (2.28-8.30) | <.001 |
| Donor type | |||
| HLA-matched relative | 83/677 | 1.00 | <.001 |
| HLA-mismatched relative | 25/78 | 3.30 (1.93-4.77) | <.001 |
| HLA-matched unrelated | 19/252 | 1.13 (0.64-2.02) | .67 |
| HLA-mismatched unrelated | 15/103 | 1.56 (0.85-2.88) | .16 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 25/376 | 1.00 | <.001 |
| Bu/Cy/FLU | 22/259 | 1.32 (0.74-2.34) | .34 |
| Bu/Cy | 55/249 | 3.61 (2.15-6.07) | <.001 |
| Treosulfan/TT/FLU | 30/169 | 2.22 (1.23-4.030 | .008 |
| Bu or melphalan ± TT ± FLU | 10/57 | 2.55 (1.18-5.50) | .02 |